Xeris Biopharma Holdings (XERS) Share-based Compensation (2020 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Share-based Compensation came in at $17.0 million in Q1 2026, up 112.77% YoY from $8.0 million in Q1 2025, and up 373.67% on a QoQ basis from -$6.2 million in Q4 2025.
Xeris Biopharma Holdings (XERS) Share-based Compensation (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 7 years of Share-based Compensation data on file, last reported at $17.0 million in Q1 2026.
- Quarterly Share-based Compensation rose 112.77% year-over-year to $17.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.9 million (up 149.78% YoY) and the FY2025 annual result came in at $10.9 million, up 191.27% from the prior year.
- Share-based Compensation grew to $17.0 million in Q1 2026, from -$6.2 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $20.0 million in Q2 2023 to a low of -$6.2 million in Q4 2025.
- A 5-year average of $5.0 million and a median of $2.9 million in 2022 frame the typical range for Share-based Compensation.
- The widest YoY moves for Share-based Compensation: up 9108.43% in 2025, down 3845.78% in 2025.
- Tracing XERS's Share-based Compensation over 5 years: stood at $12.2 million in 2022, then plunged by 99.6% to $49000.0 in 2023, then jumped by 238.78% to $166000.0 in 2024, then sank by 3845.78% to -$6.2 million in 2025, then surged by 373.67% to $17.0 million in 2026.
- The last three Share-based Compensation figures came in at $17.0 million (Q1 2026), -$6.2 million (Q4 2025), and $7.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 40.00 Mn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 26.00 Mn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 114.12 Mn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 19.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 30.40 Mn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 65.00 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 7.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Xeris Biopharma Holdings | 1.51 Bn | 1.39 Bn | 79.59 Mn | 191,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 191,000.00 |
| Jun 30, 2026 | 191,000.00 |
| Mar 31, 2026 | 17.02 Mn |
| Mar 31, 2026 | 17.02 Mn |
| Dec 31, 2025 | -6.22 Mn |
| Dec 31, 2025 | -6.22 Mn |
| Sep 30, 2025 | 7.64 Mn |
| Sep 30, 2025 | 7.64 Mn |
| Jun 30, 2025 | 1.45 Mn |
| Jun 30, 2025 | 1.45 Mn |
| Mar 31, 2025 | 8.00 Mn |
| Mar 31, 2025 | 8.00 Mn |
| Dec 31, 2024 | 166,000.00 |
| Dec 31, 2024 | 166,000.00 |
| Sep 30, 2024 | 83,000.00 |
| Sep 30, 2024 | 83,000.00 |
| Jun 30, 2024 | -282,000.00 |
| Jun 30, 2024 | -282,000.00 |
| Mar 31, 2024 | 3.77 Mn |
| Mar 31, 2024 | 3.77 Mn |